OnCo
peoplePerson

Rui-Hua Xu

Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.

Rui-Hua Xu is a gastrointestinal oncologist whose trials (including JUPITER-06 toripalimab in oesophageal cancer and studies of camrelizumab, fruquintinib, and anti-EGFR therapy) established immunotherapy and targeted therapy for Chinese GI cancer patients; he is president of SYSUCC.

Role
President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology
Specialisms
Gastrointestinal oncologyColorectal cancerOesophageal and gastric cancerImmunotherapy

Papers

1top
TitleJournalYear
Toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma (JUPITER-06)Cancer Cell2022

Key papers

1top
rctThe Lancet 2023changed practice
SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer

Patients with newly diagnosed advanced stomach cancer should now have Claudin 18.2 tested alongside HER2, PD-L1 and mismatch repair, because roughly a third will be eligible for zolbetuximab, which adds about three months of median survival. The main practical problem is nausea and vomiting during infusions, which needs aggressive prophylaxis. How to sequence or combine it with immunotherapy in PD-L1-positive tumours is unresolved.

Connected

10top

Pages like this

not linked directly; found by shared links

cancers

3
Colorectal cancerGastric & gastro-oesophageal junction cancerOesophageal cancer

drugs

3
Under reviewMonoclonal antibody (anti-PD-1)
Camrelizumab · AiRuiKa
ApprovedSmall-molecule kinase inhibitor (VEGFR1-3)
Fruquintinib · Fruzaqla
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi

institutions

2
Chinese Society of Clinical OncologySun Yat-sen University Cancer Center

trials

1
ESCORT-1st

key papers

1
SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer